

# EXECUTIVE SUMMARY

JANUARY-SEPTEMBER 2021




## Main figures €m

<b>REVENUE</b> 463.5 (+53%)	<b>EBITDA</b> 139.5 (+100%)	<b>EBIT</b> 123.3 (+123%)
<b>Net profit</b> 98.9 (+111%)	<b>Capex</b> 22.0 (30%)	<b>Net cash</b> 74.4


**2022 operating revenue guidance:** ROVI expects a mid-single-digit growth rate for the operating revenue

"ESG Risk Rating 2021" of 18.4, which places the company at low risk (between 10 and 20). ROVI has attained the second position out of 432 companies in the subindustry "pharmaceuticals".

## Operating revenue €m



## Specialty pharma business €m



**Heparin franchise\*** €181.5 (+15%) 39% of operating revenue

**LMWH** €176.2 (+15%)

### Bemiparin sales

€86.3m (+13%)

Spain €51.8m (+3%)

International €34.5m (+32%)

### Enoxaparin sales

€89.9m (+17%)

✓ Directly marketed in Germany, UK, Italy, Portugal, Spain and Poland

✓ Launched in 28 countries.


✓ Approved in 26 countries in Europe and 24 in RoW

\* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins


## CMO business €m

Total €180.2m (+187%)


## Gross margin €m



## SG&A expenses €m



## EBITDA €m



EBITDA Pre-R&D<sup>1</sup>  
€m

€158.6m

+86%


## R&D expenses €m

€19.1

+22%

Product	Potential Indication	Current Situation	Key Milestones
DORIA® Risperidone, monthly	Schizophrenia	Phase III	In approval process in Europe and in USA
Letrozole ISM® Long acting Letrozole	Breast Cancer	Phase I	Phase I started in November 2017
Risperidone, quarterly	Schizophrenia	Non-Clinical	
Concentrated on improving posology for already approved compounds, which benefits risk / reward profile			
Multiple FDA / GMP approved facilities to support the platform			

## NET PROFIT €m



Net profit Pre-R&D<sup>1</sup>  
€m

€114.1m

+89%

## News flow

### SPECIALTY PHARMA

- Sales of enoxaparin biosimilar
- Additional new products to be launched
- Granting by the competent local authorities of the marketing authorization of an Enoxaparin biosimilar outside Europe

### CMO

- New contracts to be announced
- Evolution of Moderna's vaccine manufacturing.

### ISM® Technology platform

- Marketing authorisation for Risperidone ISM® in Europe and USA
- Discussions with FDA initiated to review Letrozole ISM® phase I results as well as next steps

<sup>1</sup>. Calculated excluding R&D expenses in 9M 2021 and 9M 2020